People and Partners

PharmaFutures 2 brought together pharmaceutical executives and representatives of the financial community in a Working Group. The project was run by a Secretariat, composed of the Project Director and administrative support. SustainAbility was contracted to provide research and facilitation skills.

The Working Group was composed of the following people, who during the time of the project were employed in the capacity outlined.

Working Group Members

  • Stewart Adkins, Stewart Adkins Advisors Limited
  • Paulo Costa, Novartis
  • Martin Eijgenhuijsen, ABP Investments
  • Lise Kingo, Novo Nordisk A/S
  • Dr Niall Kirk, F&C Management
  • Dr. Guy J. Lebeau, Johnson & Johnson
  • Robert L. Mallett, Pfizer Inc.
  • John McHale, Pioneer Investment Management Ltd
  • Viren Mehta, Mehta Partners
  • David Y. Norton, Johnson & Johnson
  • John Schaetzl, GE Asset Management
  • Scott Streator, Ohio Public Employees Retirement System (OPERS)
  • Daniel Summerfield, Universities Superannuation Scheme (USS)
  • Ian Talmage, Bayer
  • Lynn A. Tetrault, AstraZeneca PLC
  • Andrew Witty, GlaxoSmithKline

SustainAbility team

  • Sophia Tickell, Project Director
  • Ritu Khanna, Project Manager, SustainAbility
  • Mark Lee, CEO
  • John Elkington, Founder & Chief Entrepreneur
  • Peter Zollinger, Senior Vice President
  • Meghan Chapple-Brown, Director


Download PharmaFutures 2


I have watched the industry suffer the loss of public trust, struggle with bringing new products to market and lose the ability to grow its top line. This perfect storm is reflected in the current share price and as a long term investor I hope to hear and perhaps help find the early signs of a path to recovery.

John Schaetzl, Independent